Addex Therapeutics invested CHF 2 million in Stalicla, a clinical-stage company focusing on precision medicine for neurodevelopmental disorders. The investment supports Stalicla's autism drug candidates and clinical trials, with Addex CEO Tim Dyer joining Stalicla's Board of Directors.
Stalicla, a Swiss clinical-stage biotech company, secured CHF 2 million in financing from Addex Therapeutics to advance its precision medicine neurodevelopmental disorder programs, including preparing for Series C financing and progressing clinical trials for autism and substance use disorder treatments.
Addex Therapeutics reported a strong cash position of CHF2.8 million at the end of Q1 2025. The company's GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models, and it regained rights to its phase 2 mGlu2 PAM asset.
Addex Therapeutics, a clinical-stage biopharmaceutical company, announced that it will issue its Q1 2025 financial results and provide a business update on June 19, 2025. The company's GABAB PAM candidate has demonstrated robust anti-tussive activity in multiple chronic cough preclinical models.
Addex Therapeutics announced that it will present preclinical data on its GABAB positive allosteric modulator cough program at the American Cough Conference. The company's lead drug candidate is ready to start IND enabling studies.
Addex Therapeutics announced that its partner Janssen Pharmaceuticals has returned the development and commercialization rights to ADX71149, a drug candidate for neurological disorders. Addex is now evaluating future development options for the program.
Addex Therapeutics reported a net loss of CHF 1.5 million in Q3 2024, compared to a net profit of CHF 12.9 million in Q2 2024, primarily due to the sale of part of the business to Neurosterix. However, the nine-month results remain positive, with a net profit of CHF 8.3 million.
Addex Therapeutics announced that its partner Janssen Pharmaceuticals has discontinued the development of ADX71149 in epilepsy after the Phase 2 study did not meet the primary endpoint. The companies will continue to analyze the full data set to determine the future of the asset.
Addex Therapeutics presented positive results from its GABAB positive allosteric modulator (PAM) chronic cough program at the 13th London International Cough Symposium. The GABAB PAM candidate showed significant and dose-dependent reduction in cough frequency, increased cough latency, and no signs of tolerance in...
Addex Therapeutics, a biopharmaceutical company, announced that its Head of Translational Science, Mikhail Kalinichev, will present on the antitussive activity of a novel GABAB receptor positive allosteric modulator in preclinical models of chronic cough at the Thirteenth London International Cough Symposium.
● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024.
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it will issue its Q1 2024 Financial Results on June 6, 2024. Tim...
Geneva, Switzerland, May 8, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Bio€quity Europe 2024 conference taking place May 12 - 14, 2024 at the Kursaal Congress...
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April 22 - 23, 2024 at the Congress...
Ad Hoc Announcement Pursuant to Art. 53 LR
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates. Skillsoft posted adjusted loss of $3.09 per share, versus market estimates of $3.27 per share. The company’s quarterly sales...
Shares of Macatawa Bank Corporation (NASDAQ: MCBC) rose sharply in today’s pre-market trading after Wintrust Financial Corporation (NASDAQ: WFTC) and Macatawa Bank announced that they have entered into a definitive merger agreement for Wintrust to acquire Macatawa in an all-stock transaction. Macatawa Bank shares...
Headlines via Polygon.io. Links open the original publisher.